Form 8-K - Current report:
SEC Accession No. 0001558370-21-002811
Filing Date
2021-03-11
Accepted
2021-03-11 16:02:46
Documents
14
Period of Report
2021-03-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nbrv-20210311x8k.htm   iXBRL 8-K 36738
2 EX-99.1 nbrv-20210311xex99d1.htm EX-99.1 284836
3 GRAPHIC nbrv-20210311xex99d1001.jpg GRAPHIC 5994
  Complete submission text file 0001558370-21-002811.txt   472101

Data Files

Seq Description Document Type Size
4 EX-101.SCH nbrv-20210311.xsd EX-101.SCH 3031
5 EX-101.LAB nbrv-20210311_lab.xml EX-101.LAB 16027
6 EX-101.PRE nbrv-20210311_pre.xml EX-101.PRE 10358
7 EXTRACTED XBRL INSTANCE DOCUMENT nbrv-20210311x8k_htm.xml XML 4854
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 21733236
SIC: 2834 Pharmaceutical Preparations